Field Medical Closes Oversubscribed $35 Million Series B to Advance Development of FieldForce™ Pulsed Field Ablation Platform

CARDIFF-BY-THE-SEA, Calif., [July 1, 2025] /PRNewswire/ — Field Medical, Inc., a clinical-stage company redefining cardiac ablation with next-generation pulsed field ablation (PFA) technology, today announced the close of a $35 million Series B financing round co-led by BioStar Capital and Cue Growth, with participation from existing strategic investors.

Read the full press release here.